There is no sufficient reason to give “last hope” drugs approval and funding

Research output: Other contributionAcademic

Original languageEnglish
TypeCPLB Dilemmas, Rutgers University [Peer-reviewed article]
PublisherCenter for Population-Level Bioethics, Rutgers University
Place of PublicationNew Brunswick, NJ
Publication statusPublished - 7-May-2024

Publication series

NameCPLB Dilemmas: Dilemma #8, Should “last hope” drugs get priority approval and funding over other drugs even when they otherwise offer a less favorable balance of risks to prospective benefits?

Cite this